Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 48 Week, Phase II, Open-Label, 2-Cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-Experienced Pediatric Subjects Aged 4 Weeks to greater than 2 Years.

Next Previous
Trial Profile

A 48 Week, Phase II, Open-Label, 2-Cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-Experienced Pediatric Subjects Aged 4 Weeks to greater than 2 Years.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosamprenavir (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ViiV Healthcare

Most Recent Events

  • 01 Oct 2024 Results assessing safety and efficacy results through Week 684 for pediatric participants living with HIV-1 treated with ritonavir-boosted fosamprenavir oral solution-based antiretroviral therapy published in the AIDS Research and Human Retroviruses
  • 09 Oct 2023 Status changed from active, no longer recruiting to completed.
  • 04 Jun 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Nov 2016)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top